Please login to the form below
CAR-T therapy
This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
treatment. However today England’s cost effectiveness watchdog NICE has issued a draft ruling that the CAR-T therapy cannot be recommended because it is not cost effective in diffuse large ... This is far from surprising – NICE has already come to
Latest news
-
Gilead optimistic about Yescarta deal in UK
That’s because Gilead’s CAR-T therapy is a potentially life-saving cancer therapy, wiping out all traces of advanced cancer in around half of the patients who received it ... Yescarta (axicabtagene ciloleucel) and its rival CAR-T therapy
-
Novartis’ CAR-T Kymriah gets green light in England
Novartis has set a “fair and affordable”price for its CAR-T therapy Kymriah that should make it available for up to 30 children every year with acute lymphoblastic leukaemia (ALL), ... NHS England's Simon Stevens. NHS England chief executive Simon
-
Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question
It’s been struggling with production issue for the CAR-T since its US launch, specifically variability in product specifications that in some cases have led to manufacturing failures. ... includes selecting treatment centres, training staff in CAR-T
-
Armoured CAR ‘could overwhelm solid tumour resistance’
Armoured CAR ‘ could overwhelm solid tumour resistance’. A souped-up version of chimeric antigen receptor (CAR) T-cell therapy has shown it can improve the targeting of solid tumours. ... The armoured CARs enhanced the survival of the mice, according
-
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka
France’s CAR-T therapy contender Cellectis has hired a senior Novartis scientist to be its head of clinical development. ... He is joining an ambitious effort by Cellectis: it is aiming to be the first to bring an ‘off the shelf’or allogeneic CAR-T
More from news
Approximately 4 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’CAR-T ... Its fourth pipeline candidate is the multiple myeloma
-
No incentive for a cure
These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... One of the biggest questions with a curative
-
Can value-based healthcare take off and reach for the skies?
CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
The rise of real-world evidence
Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.
-
Deal Watch January 2018
Having terminated the development of its lead CAR-T therapy, JCAR015, early last year after several patient deaths in a phase II clinical trial in relapsed/refractory B-cell acute lymphoblastic ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... It could also receive additional, undisclosed milestones if the CAR-T
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October.
-
Innovation in pharma: the highs and lows of the current healthcare economy
Gene therapies often require a ‘ one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Healthcare PR Senior Account Manager
-
Salary TBC
-
Associate Scientific Director
-
Salary TBC
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Sudler London - Account Director
-
Competitive
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Medical Writers Required - Hertfordshire
-
Competitive
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Systematic Review Lead- London
-
Negotiable
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director or Senior Account Director
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Writer, Healthcare Advertising, London
-
Excellent package
Subscribe to our email news alerts
- Lucid limbers up for second annual sports day
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- Hanover Health launches award, Firstlight spins off healthcare arm and more
- J&J files ‘breakthrough’ bladder cancer drug in US
- Boehringer’s Corsico to be new GSK drug dev leader
- More tell, less sell: HCP-centric comms
PMHub
wethepeople
wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
